A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

BACKGROUND: This study compared efficacy and safety of TA4415V, a trastuzumab biosimilar, with reference trastuzumab in patients with human epidermal growth factor receptor 2–positive (HER2-positive) early-stage breast cancer treated in the neoadjuvant setting in Iran. METHODS: Patients were randoml...

Descripción completa

Detalles Bibliográficos
Autores principales: Nodehi, Reza Safaei, Kalantari, Behjat, Raafat, Jahangir, Ansarinejad, Nafiseh, Moazed, Vahid, Mortazavizadeh, Seyed Mohammad Reza, Hosseinzadeh, Mehran, Ghaderi, Bayazid, Jenabian, Arash, Qadyani, Mojtaba, Haghighat, Shirin, Allahyari, Abolghasem, Mirzania, Mehrzad, Seghatoleslami, Mohammad, Payandeh, Mehrdad, Alikhasi, Afsaneh, Kafi, Hamidreza, Shahi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336069/
https://www.ncbi.nlm.nih.gov/pubmed/35902898
http://dx.doi.org/10.1186/s40360-022-00599-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336069/
https://www.ncbi.nlm.nih.gov/pubmed/35902898
http://dx.doi.org/10.1186/s40360-022-00599-x

Ejemplares similares